Systemic and coronary hemodynamic effects of the new dihydropyridine calcium antagonist nisoldipine were studied over a 30-minute period in 12 patients with angina pectoris. Previously instituted p-blocker therapy was continued. Nisoldipine was administered in an intravenous bolus of 6 pg/kg over 3 minutes. Heart rate increased as mean aortic pressure and systemic vascular resistance decreased in all patients. Cardiac output increased significantly, from 5.6 f 0.3 to 7.9 f 0.5 liters/min, 10 minutes after nisoldipine infusion. These trends were maintained over the 30-minute observation period. Coronary sinus blood flow increased from 103 41 11 to 139 f 13 ml/min immediately after nisoldipine, but had returned to the control level by 30 minutes, as had the reduction in coronary vascular resistance. Myocardial oxygen consumption and heart ratesystolic blood pressure product did not change significantly. Nisoldipine is a potent peripheral and coronary vasodilator free of major myocardial depressant effects after acute intravenous administration. The systemic vasodilatory effects appear to outlast the coronary effects over 30 minutes.
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(Am J Cardiol 1966;58: [1199] [1200] [1201] [1202] [1203] N isoldipine is a calcium channel blocking agent of the dihydropyridine class, similar in chemical structure to nifedipine.',' Nisoldipine has 4 to 10 times the potency of nifedipine in inhibiting vascular smooth muscle, but is less potent in the inhibition of isolated heart muscle.3 Nisoldipine may have a preferential effect on the coronary vasculature in vivo,4 a potentially desirable effect for treatment of myocardial ischemia. The acute effects in humans of intravenous nisoldipine on coronary and peripheral vasculature and left ventricular function were recently shown.5-6 The increase in heart rate after nisoldipine administration and the lack of observed negative inotropic effects indicate that in clinical usage, nisoldipine may be combined with a /3-adrenergic blocking drug. Therefore, in this study the patients continued to receive any prescribed P-blocking drug. The aim was to investigate the persistence of hemodynamic changes induced by a bolus of nisoldipine over a 30-minute study period.
Methods
Twelve patients (10 men, 2 women] undergoing cardiac catheterization for investigation of suspected coronary artery disease were studied. Mean age was 54 years (range 37 to 64) ( Table I ]. All medications except /3-adrenergic blocking drugs were discontinued at least 24 hours before the study. Beta-blocker therapy was continued in the dose prescribed by the referring physician. Cardiac catheterization was performed with the patient fasting and without premeditation using a right antecubital approach. A Webster coronary sinus thermodilution catheter was positioned to allow recording of coronary sinus blood flow by the continuous thermodilution technique7 and sampling of blood for oxygen saturations. The catheter position was determined by initial contrast injection and subsequent fluoroscopy and was kept stable. A No. 7Fr Swan-Ganz thermodilution catheter was positioned with the tip at the bifurcation of the main pulmonary artery for pressure measurements and determination of cardiac output. A No. 8Fr Millar pigtail catheter with tip manometer for pressure recording was positioned in the ascending aorta. Blood for aortic oxygen saturation could be taken through this catheter.
Nisoldipine, 6 pg/kg, was infused intravenously over 3 minutes, with care taken to minimize exposure to light. Heart rate, coronary sinus blood flow, aortic, pulmonary and right atria1 pressures, aortic and coronary sinus oxygen saturations and cardiac output were measured in the control state before nisoldipine infusion and as close as possible to lo,20 and 30 minutes after completion of the infusion. Heart rate, oxygen saturations and coronary sinus blood flow were measured again immediately upon cessation of nisoldipine infusion and hemoglobin levels were determined before and after the study. Standard left ventriculography and coronary angiography were then performed. Left ventricular ejection fractions were calculated from the right anterior oblique projection. Aortic and coronary sinus oxygen contents were given by hemoglobin (g/l00 ml) X oxygen saturation X 1.36, myocardial oxygen consumption by coronary blood flow X aortocoronary sinus oxygen difference and peripheral vascular resistance by the ratio of mean aortic -right atria1 pressure difference to cardiac output. Coronary vascular resistance was given by the ratio of mean aortic pressure to mean coronary blood flow. Statistical analysis: Values are mean f standard error of the mean, using .&way analysis of variance (Duncan new multiple-range test) for repeated measurements. When overall significance was found, multiple comparisons were used to delineate which paired comparisons were significantly different at the 0.05 level.
Results
Ten patients were taking p-blocking drugs and 11 had significant coronary artery disease, defined as at least 50% luminal diameter narrowing in a major coronary artery. Mean ejection fraction was 0.59 (range 0.35 to 0.74). There was no difference in hemoglobin values measured before and after the study. Patient clinical and angiographic data are summarized in Table 1. No patient had angina pectoris or other untoward symptoms during the study.
Heart rate increased and systemic vascular resistance decreased with a decrease in mean aortic pressure in all patients (Fig. 1) . Cardiac output had increased from 5. surements are displayed in Figure 2 . An increase in coronary sinus blood flow occurred in all patients, as did a fall in coronary vascular resistance. 
Discussion
This study confirms the persistence of some hemodynamic effects over 30 minutes after an intravenous bolus of nisoldipine. Heart rate, stroke volume and cardiac output remained elevated at 30 minutes, aortic pressures and systemic vascular resistance were decreased. In this regard nisoldipine mimics the effects of nifedipine with afterload reduction inducing reflex sympathetic activation8
Since approximately 857~ of coronary sinus blood flow arises from the left ventricle,9 measurements reflect left ventricular coronary flow. Research data support a very close link between myocardial oxygen demand and coronary blood flow, with the changing oxygen requirements producing alterations in coronary vascular resistance and flow on a beat-to-beat basis.'" Thus, the increase in flow observed after nisoldipine in the face of an unchanged myocardial oxygen consumption reflects a perfusion of the left ventricle in excess of demand, one means by which calcium antagonists may be beneficial in the treatment of ischemia. To be beneficial, such increased supply should be distributed to ischemic or potentially ischemic myocardiurn as well as to normal area. In dogs with acutely occluded left anterior descending arteries, nisoldipine increases coronary collateral flow to the ischemic zone, with equal distribution to the subendocardium and subepicardium. l1 A study of 10 patients with coronary artery disease, using a C-l4 lactate infusion and coronary sinus lactate estimations, suggested that nisoldipine reduced lactate production by chronically underperfused myocardium.lz While increased oxygen supply was considered to play a part, dipyridamole, a powerful coronary dilator, has few antianginal properties and does not improve myocardial lactate metabolism, indicating that other actions of nisoldipine may be operative in myocardial ischemia. Reduction of left ventricular preload is considered an important component of the antianginal action of nitrates. While nifedipine has little such tendency,13 nisoldipine was shown to reduce markedly left ventricular end-diastolic pressure in fluid-loaded pigs without depression of myocardial contractility.14 It was suggested that antianginal effects of nisoldipine may include correction of impaired ventricular relaxation with reduction in diastolic wall stress. At lo,20 and 30 minutes, a greater degree of reduction in vascular resistance was present in the systemic than in the coronary system [Fig. 4) . In an earlier study coronary vascular resistance was reduced by 50% immediately after nisoldipine, while systemic vascular resistance was reduced by 3O%, suggesting relative selectivity for the coronary vasculature.5 Such selectivity could result from an increased number of nisoldipine receptor sites or receptors of greater sensitivity in the coronary vascular wall, The duration and degree of systemic effects of nisoldipine in the current study may be due to the fact that coronary vascular autoregulation became operative within the 30-minute observation period. Although the mediators of this control that couples vascular resistance to myocardial metabolism are unknown, adenosine and other nucleotides, prostaglandins, carbon dioxide and hydrogen ions have been proposed as possibilities. Although autoregulation is not unique to the coronary circulation and also occurs in peripheral vascular beds, coronary autoregulatory mechanisms may be more potent in effecting a return of the nisoldipine-induced changes toward control. Other explanations for the observed changes include peripheral vascular selectivity for nisoldipine rather than coronary selectivity3 or disparate effects on the coronary vasculature of vasoconstrictors such as noradrenaline released by reflex sympathetic mechanisms.
Beta-blocking drugs used alone produce reductions in myocardial oxygen consumption, increase coronary vascular resistance15,16 and reduce blood flow,17 changes that may increase sensitivity to the vasodilator effects of nisoldipine. The lack of control data before P-blocker therapy makes it difficult to speculate on the additive effects in the 10 patients taking these medications. Certainly the increase in heart rate was similar to that observed in the previous study, in which Pblocker therapy was discontinued.5J Some patients were, however, using P-blocker dosages lower than those generally recommended, and the rest heart rate in a few suggests suboptimal /3 blockade. Studies with nifedipine and ,&blocking drugs show attenuation of the reflex positive inotropic and chronotropic changes.17J8 As the increase in heart rate after nisoldipine tended to offset any reduction in cardiac work, the combination with p blockade may be beneficial.
The increase in right heart pressures probably reflects the increase in venous return. The absence of venodilatory effects has been shown for nifedipine,lg but has not been investigated in humans for nisoldipine.
In a recent study on open-chested anesthetized dogs, nisoldipine reduced myocardial infarct size after coronary occlusion by 31.4% .2o This was considered to be in part a result of afterload reduction with reduced left ventricular wall stress, as it was pointed out that other agents producing afterload reduction such as nitroprusside have been ineffective in preventing ischemic myocardial damage.z1z22 Other animal experiments with nisoldipine show it to be useful in preventing ventricular arrhythmias resulting from acute myocardial ischemia in ratsz3 and effective in preventing ATP breakdown in the ischemic rat heart.24 In the latter study, ischemia was induced by lowering aortic perfusion and nisoldipine was given through the aorta. Nisoldipine was found to induce coronary vasodilatation at very low doses and a significant negative inotropit effect only became apparent at concentrations 30 times higher. Purine efflux from the ischemic hearts was suppressed in a dose-dependent fashion, suggesting preservation of myocardial ATP. A direct effect on myocardial enzyme levels was postulated. With the afterload-reducing properties of nisoldipine, the lack of significant negative inotropic effects from doses producing the vascular changes and the possibility of reducing infarct size, the drug may have clinical usefulness for treatment of acute myocardial infarction complicated by increased systemic blood pressure.
